No Survival Benefit With Immune Checkpoint Inhibitor Rechallenge in Metastatic RCC

(MedPage Today) -- CHICAGO -- Adding atezolizumab (Tecentriq) to cabozantinib (Cabometyx) for patients with metastatic renal cell carcinoma (RCC) after progression on an immune checkpoint inhibitor failed to improve clinical outcomes and led...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news